Combining nanoscale PI3K-targeting supramolecular therapeutics with anti-PD-L1/PD-1 Ab exhibited a synergetic anticancer effect in breast cancer in vivo (Kulkarni et al., 2016). The gene discussed is PIK3CD; the disease is breast cancer.